IP Library Granted Patent US 11,634,695
Granted Patent B2
US 11,634,695 · App. 17/072,910 · Granted Apr 25, 2023

Vectors for expression of biocatalysts

Inventors: Jovana Nazor (Milpitas, CA); Robert Osborne (Raleigh, NC); Jack Liang (South San Francisco, CA); Jonathan Vroom (South San Francisco, CA); Xiyun Zhang (Fremont, CA); David Entwistle (San Carlos, CA); Rama Voladri (Pleasanton, CA); Ravi David Garcia (Los Gatos, CA); Jeffrey C. Moore (Westfield, NJ); Shane Grosser (Princeton, NJ); Birgit Kosjek (Westfield, NJ); Matthew Truppo (Ocean Township, NJ)
Assignee: Codexis, Inc.
C12N9/0071C12P17/12C12Y114/11C12Y114/11002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,634,695
App. No.
17/072,910
Granted
Apr 25, 2023
Kind
B2
Abstract

The present invention provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.

Claims (15)

1. An expression vector comprising a polynucleotide comprising SEQ ID NO:1007, 1008, or 1009 with up to 20 nucleotide substitutions, insertions, or deletions in the polynucleotide sequence of SEQ ID NO: 1007, 1008, or 1009.

2. The expression vector of claim 1 , additionally comprising an engineered polynucleotide encoding an engineered polypeptide, wherein said engineered polypeptide is capable of converting (S)-pipecolic acid to (2S,5S)-5-hydroxypipecolic acid with greater than 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% diastereomeric excess of (2S,5R)-5-hydroxypipecolic acid.

3. The expression vector of claim 1 , further comprising at least one control sequence.

4. The expression vector of claim 3 , wherein said at least one control sequence comprises a ribosome binding site.

5. The expression vector of claim 3 , wherein said at least one control sequence comprises an Escherichia coli lac operon.

6. The expression vector of claim 1 , further comprises a chloramphenicol resistance gene.

7. The expression vector of claim 2 , wherein said engineered polynucleotide encoding an engineered polypeptide comprises a nucleic acid sequence optimized for expression in Escherichia coli.

8. A host cell comprising the expression vector of claim 1 .

9. A host cell comprising the expression vector of claim 2 .

10. The host cell of claim 8 , wherein the host cell is Escherichia coli.

11. The host cell of claim 9 , wherein the host cell is Escherichia coli.

12. A method of preparing an engineered polypeptide, comprising culturing the host cell of claim 9 , under conditions suitable for expression of the polypeptide.

13. The method of claim 12 , further comprising a step of isolating the engineered polypeptide.

14. A method of preparing an engineered polypeptide, comprising culturing the host cell of claim 10 , under conditions suitable for expression of the polypeptide.

15. The method of claim 14 , further comprising a step of isolating the engineered polypeptide.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (4)
Continuation 16196205 · Nov 20, 2018
Division 15491692 · Apr 19, 2017
Provisional Application 62347724 · Jun 9, 2016
Related Publication 20210032605A1 · Feb 4, 2021
Cited By (1)
US 12,286,648